contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


lumito-signs-letter-of-intent-with-scientific-advisor

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Lumito

Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development.Paul Waring is a highly...

<div class="mfn-preamble"><p><strong>Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development.</strong></p></div><div class="mfn-body"><p>Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between Genentech and Ventana Medical and built large organizations around cancer biomarkers within Genentech and Astra Zeneca. He has been Director of Pathology at the Peter MacCallum Cancer Center in Melbourne and Professor and Chief Pathologist at Melbourne University. In addition to senior positions at AstraZeneca and Genentech, he has been Vice President of Medical Innovation at Roche Tissue Diagnostics.</p><blockquote>"We are very pleased that Paul Waring sees the potential of our product and has chosen to become our first scientific advisor. We met Paul during the congress in Florence in September, and I am really glad that we already have a collaboration in place. We look forward to working with Paul and learning from his extensive experience and insights. He has been instrumental in translating new insights and innovations into clinical routine use in previous positions," says Lumito CEO Sanna Wallenborg.</blockquote><blockquote>"The most important things for me are belief that the technology has the potential to address an unmet clinical need and has a commercial opportunity, synergy with my other activities, absence of conflict of interest, that I like and respect the people I am working with and that there is a long term relationship so that I am genuinely engaged and part of the team and the company’s success.&nbsp;Lumito ticks all the boxes for me," says Paul Waring.</blockquote></div><div class="mfn-footer mfn-contacts mfn-1c72a901341e"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Sanna Wallenborg, CEO Lumito<br>E-mail:&nbsp;<a rel="noopener" href="mailto:sw@lumito.se">sw@lumito.se</a><br>Ph: +4670-870 01 68</p></div><div class="mfn-footer mfn-about mfn-a888ce5bf1d4"><p><strong class="mfn-heading-1">About Lumito</strong></p><hr><p><strong>Lumito</strong>&nbsp;specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The&nbsp;company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre.&nbsp;<a rel="noopener" href="http://www.lumito.se/en">www.lumito.se/en</a></p><p>The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-image"><p><strong class="mfn-heading-1">Image Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/243972ee-25fa-4b05-b71c-a46ec4828619/paul-waring.jpeg">Paul Waring</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/e58c95e3-d4a9-410e-805b-e6aad80bcd30/lumito-signs-letter-of-intent-with-scientific-advisor.pdf" class="mfn-generated mfn-primary">Lumito signs Letter of Intent with Scientific Advisor</a></p></div>